Q3 Earnings Forecast for NRIX Issued By Leerink Partnrs

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Leerink Partnrs issued their Q3 2025 earnings per share estimates for Nurix Therapeutics in a report issued on Monday, March 17th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings of ($0.96) per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at ($3.79) EPS and FY2026 earnings at ($3.32) EPS.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%.

Other equities analysts also recently issued reports about the stock. Stephens restated an “overweight” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Needham & Company LLC lowered their price target on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. Royal Bank of Canada increased their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Stifel Nicolaus boosted their target price on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Finally, HC Wainwright upped their price target on shares of Nurix Therapeutics from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $30.88.

Nurix Therapeutics Trading Down 0.2 %

Nurix Therapeutics stock opened at $13.87 on Thursday. Nurix Therapeutics has a 1-year low of $11.90 and a 1-year high of $29.56. The company has a fifty day simple moving average of $17.10 and a 200 day simple moving average of $20.88. The company has a market cap of $1.05 billion, a P/E ratio of -4.80 and a beta of 2.18.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. US Bancorp DE raised its position in shares of Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after buying an additional 842 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Nurix Therapeutics during the 4th quarter worth $28,000. Quarry LP raised its holdings in Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after acquiring an additional 2,435 shares in the last quarter. Aquatic Capital Management LLC bought a new stake in shares of Nurix Therapeutics during the 4th quarter valued at $87,000. Finally, Summit Investment Advisors Inc. lifted its position in shares of Nurix Therapeutics by 13.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock valued at $138,000 after acquiring an additional 877 shares during the period.

Insiders Place Their Bets

In related news, insider Gwenn Hansen sold 3,690 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the sale, the chief financial officer now owns 39,549 shares of the company’s stock, valued at $785,047.65. This trade represents a 6.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,326 shares of company stock worth $213,449 over the last three months. Insiders own 7.20% of the company’s stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.